Trial Profile
A Retrospective Cohort Study Investigating the Management and Outcomes of Chronic-Lymphocytic-Leukaemia (CLL) Patients Treated with Venetoclax (VEN) in the Real World Setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2018
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 29 Jun 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association
- 05 Jun 2018 Results (n=222) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.